Gene expression profiling studies have shown aberrant expression of DIS3 in a small range of different cancers [18,19,20,21,22,23,24] and recently whole genome/whole exome and amplicon sequencing studies have revealed DIS3 to be recurrently mutated in multiple myeloma [25,26,27,28,29]. The gene discussed is DIS3; the disease is plasma cell myeloma.